US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

Clearmind Medicine Inc

us-stock
To Invest in {{usstockname}}
us-stock
$0.112 -0.1427(-14.27%) CMND at 04 Dec 2025 04:28 PM Biotechnology
Lowest Today 0.1
Highest Today 0.1147
Today’s Open 0.10675
Prev. Close 0.1296
52 Week High 2.18
52 Week Low 0.10
Day’s Range: Low 0.1 High 0.1147
52-Week Range: Low 0.10 High 2.18
1 day return -
1 Week return -24.34
1 month return -85.35
3 month return -88.66
6 month return -88.38
1 year return -91.28
3 year return -99.89
5 year return -
10 year return -

Institutional Holdings

Gotham Asset Management, LLC 6.40

AdvisorShares Investments, LLC 3.83

AdvisorShares Psychedelics ETF 3.71

Cornerstone Wealth Group, LLC 0.37

XTX Topco Ltd 0.21

JPMorgan Chase & Co 0.07

Morgan Stanley - Brokerage Accounts 0.05

Royal Bank of Canada 0.01

Advisor Group Holdings, Inc. 0.01

Citadel Advisors Llc 0.00

Tower Research Capital LLC 0.00

TWO SIGMA SECURITIES, LLC 0.00

Virtu Financial LLC 0.00

Market Status

Fundamentals

Market Cap 4.30 M

PB Ratio 4.5802

PE Ratio 0.0

Enterprise Value 1.41 M

Total Assets 7.26 M

Volume 23114727

Company Financials

Annual Revenue FY24:0 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY24:-26703 -0.0M, FY23:-77566 -0.1M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY24:-5254678 -5.3M, FY23:-11627302 -11.6M, FY22:-9410806 -9.4M, FY21:-4122652 -4.1M, FY20:-233220 -0.2M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-11970 -0.0M, Q1/2025:-12038 -0.0M, Q4/2024:-11512 -0.0M, Q3/2024:-15191 -0.0M

Quarterly Net worth Q3/2025:-1313592 -1.3M, Q2/2025:-783928 -0.8M, Q1/2025:-1071621 -1.1M, Q4/2024:-884744 -0.9M, Q3/2024:-2093917 -2.1M

Fund house & investment objective

Company Information Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. The company develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; Yissum Research Development Company of the Hebrew University of Jerusalem to develop, manufacture, and commercialize compounds targeted at treating post traumatic stress disorder and other health conditions. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is based in Vancouver, Canada.

Organisation Biotechnology

Employees 0

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right